CLARITY CORE’s Post

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance

We announce today that we have backed Ulster University spin-out Dia Beta Labs Ltd to fund their development of a groundbreaking treatment for obesity and type 2 diabetes. We led the round from our SEIS Fund, which was also funded by QUBIS and Innovate UK. This investment marks a significant milestone for us – we now have portfolio companies in every GB nation – confirming our position as THE leading early-stage VC investing ONLY in the UK regions! Dia Beta Labs' lead candidate offers the benefits of existing GLP-1 drugs like Wegovy and Ozempic, but with significantly fewer side effects and improved long-term efficacy. Given the first generation of GLP-1s has created Europe’s biggest company in Novo Nordisk, this investment represents a massive opportunity for our investors, as well as having the potential to make a real difference in the fight against metabolic disease. Same effect, fewer side effects. You can read more about our investment here https://lnkd.in/e6a4ey-S. #obesity #type2diabetes #healthinnovation #biotech #UlsterUniversity #DSWVentures #QUBIS #InnovateUK

Pathway to Cures (P2C) was thrilled to participate in & sponsor SmartHealth Catalyzer, Inc. Best of the BioMidwest event at Portal Innovations, LLC Portal Pours event in Chicago on Wednesday, June 12th. Other sponsors included: Prendio Inotiv BioProcure, Inc. TMX Group The event featured the Top 10 Most Promising New Therapeutics and MedTech discovered at Midwest universities and research hospitals. Each company had an opportunity to pitch a request for financial support to further their research & development. Companies showcased at the event included: Andrew Cothrel, Kilele Health Brian Cunningham, Atzeyo Biosensors, Inc. Dennis Hallahan, WashU Radiation Oncology Doug Miller, Impower Health Inc Doris Benbrook, OK Safe Remedies Jed White, Tundra Targeted Therapeutics Jill Kolesar, VesiCure Technologies Paul Trippier, University of Nebraska Medical Center Steven Burns, Lighthanded Enterprises William Donaldson, Estrigenix Therapeutics, Inc. Each speaker had 4 minutes to "pitch" and share compelling reasons why they would be the best emerging biotech company venture fund investors to consider. Each attendee had 1,000 SmartHealth Catalyzer, Inc. dollars to "invest" and the biotech with the most funds raised received bragging rights. Congratulations to the winning pitch by Jill Kolesar & VesiCure Technologies who are "Harnessing the immune system to cure cancer" by focusing on Pancreas, Ovarian, & Prostate cancers. This event showcased incredibly talented researchers working on new technologies, therapies, devices, and cures to improve our global health. We encourage you to investigate what these folks are up to and consider an investment in one or more of these emerging biotechs. #biotechnology #venture #ventureinvesting #research (Below - pictured left to right: Tim Brent, Venture Principal, P2C Renee Peck, Sr. Development Director, P2C Tom Denison, CEO, SmartHealth Catalyzer Sharon A. Richardson PhD, Board Member, P2C)

Two McMaster startup companies - BiCova Therapeutics and PROVA Innovations - have received a total of $750,000 from the McMaster Seed Fund to develop and commercialize their innovative health technologies. Co-founded by Anthony Rullo, an associate professor of medicine in the Faculty of Health Sciences; and life sciences executive Robert Verhagen, BiCova Therapeutics received $500,000 to advance its novel “proximity-inducing” therapeutic platform, which can be used to treat diseases like cancer and rheumatoid arthritis. Founded by McMaster engineering and MBA graduate Matthew Rosato, PROVA Innovations Ltd. secured a $250,000 investment to enhance its WithinStride™ line of smart insoles for non-invasive in-home gait training and rehabilitation. Read more: https://lnkd.in/eyYQPikR McMaster University McMaster Industry Liaison Office (MILO) DeGroote School of Business - McMaster University McMaster Faculty of Health Sciences Faculty of Engineering - McMaster University #MadeAtMac #McMasterUniversity #Research #Innovation #Startup #Health #Technology

🙌 Congratulations to BiCova Therapeutics and PROVA Innovations Ltd. on being awarded McMaster University's Seed Fund! The McMaster Seed Fund was created to support the development of research-intensive and innovative start-ups with the potential to deliver significant economic and societal benefits to Canada. 🧬 BiCova is a novel “proximity-inducing” therapeutic platform that can be used to treat diseases like cancer and rheumatoid arthritis, and PROVA has created WithinStride™ a line of smart insoles for non-invasive in-home gait training and rehabilitation for those with Osteoarthritis. Both innovators have created solutions that are going to contribute to the development and advancement of the healthcare sector, improving patient care outcomes. This investment is going to bring the support and opportunities the founders need to advance their solutions accelerating their journey to market. 🔗 Read more about the funding here: https://lnkd.in/edxPAimE #Innovation #HealthTech #LifeSciences #Startups #Technology #Hamont

The post-COVID-19 #medtech industry continues to be a difficult space for both investors and entrepreneurs, but support for #innovation is still available for companies that can navigate the challenges of early commercialization and reimbursement, according to the presenters at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC. #TCT2024 Featuring: • Andrew Cleeland - Moderator, Fogarty Innovation • Amr Salahieh - Moderator, President and CEO of Shifamed • Jan Garfinkle - Founder and Managing Partner of Arboretum Ventures. • Todd Brinton, MD - Chief Scientific Officer, Edwards Lifesciences • Sean Salmon - President of Medtronic’s Cardiovascular Businesses • Josh Makower, MD - Professor of Medicine and Bioengineering, Stanford University; Director of the Byers Center for Biodesign (Stanford Mussallem Center for Biodesign) The 2024 MedTech Innovation Forum at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC, featured a lively discussion among industry veterans on the biggest challenges facing #medtech innovators in the coming years: https://bit.ly/3ALczuI

📢 Friday's Innov8Search Insights quick read for you to get you up to speed quickly on the last week of updates in Life Sciences.📢 There are also continued restructures and redundancies, so please get in touch if you need help. 💥 GE HealthCare is set to acquire Nihon Medi-Physics Co., Ltd. solidifying its presence in Japan’s $7 billion imaging market. NMP specializes in radiopharmaceuticals for neurology, cardiology, and oncology imaging. This move aligns with GE’s precision care strategy, with radiopharmaceuticals highlighted as a key growth driver alongside AI and new products in advancing precision medicine globally. 💥Haemonetics has agreed to sell its whole-blood business to Italy’s GVS for up to $67.1 million. The move is part of Haemonetics’ ongoing portfolio revamp aimed at boosting margins and focusing on high-growth hospital markets. The sale includes manufacturing facilities in California and Mexico, which GVS will continue operating. Analysts view the divestiture as a positive step to enhance Haemonetics’ organic growth and profitability. 💥Eli Lilly and Company's SURMOUNT-5 trial comparing thier Zepbound with Novo Nordisk's Wegovy may influence competition in the obesity treatment market in the future. 💥Edwards Lifesciences projects 8–10% sales growth in 2025, its first full year as a purely structural heart company following the $4.2 billion sale of its Critical Care business. Growth will be driven by advancements in TAVR (transcatheter aortic valve replacement) and TMTT (transcatheter mitral and tricuspid therapies), with TMTT sales expected to grow by 50–60%. Edwards highlighted opportunities in early TAVR interventions and its expanding portfolio of structural heart failure therapies as long-term growth catalysts. 💥Atlas Venture has raised $450 million for its 14th fund, maintaining its focus on early-stage biotech investments. Partner Bruce Booth emphasized the firm’s commitment to disciplined capital allocation and “seed-led venture creation,” avoiding the pitfalls of scaling too quickly. Over the past two years, Atlas has launched 16 biotech companies, supported nearly 50 clinical trials, and seen several key exits and approvals, underscoring the success of its targeted approach amidst a recovering biotech investment landscape. Justin Heath Gemma Ritchard Gemma Lennie-Sharma Innov8Search #medtechnews #biotechnews #pharmanews #innov8search #insights

Latin America's Diagnostic Breakthroughs In the current landscape of diagnostic technologies, medium throughput solutions are emerging as a significant commercial opportunity, especially in Latin America, where innovative companies are making remarkable progress. Geneprodx from Chile recently launched its diagnostic platform for thyroid nodules using Idylla technology, showcasing how medium throughput solutions can provide accurate and rapid diagnoses at a reasonable cost. TIMSER GROUP from Mexico has gained approval for its Preventix kit, aimed at early detection of cervical cancer, highlighting the effectiveness of these technologies in addressing critical medical needs. ZEV Biotech, operating in Argentina and Brazil, offers an even more integrated example with its IRIS platform, focused on antimicrobial resistance (AMR). Their fully integrated approach and commitment to medium throughput solutions allow them to address specific market niches and offer more accessible diagnostics in terms of cost and technological complexity. These ventures illustrate that the medium throughput segment is not only viable but crucial, filling a gap between low and high throughput technologies that often do not suit the realities of diagnostics in emerging markets. This segment allows for simpler implementation compared to high throughput technologies, which require significant investments in equipment and specialized training, and are more versatile than low throughput technologies, which, although simpler, are often inadequate for addressing more complex pathologies. The situation in Latin America reflects a window of opportunity for medium throughput technologies, especially as large international corporations often focus on more developed markets. This landscape provides fertile ground for local innovators like Geneprodx, TIMSER GROUP, and ZEV Biotech to advance, overcoming obstacles and setting new standards in healthcare in the region. The story of these ventures is a source of inspiration and a reminder that, although biotechnology and molecular diagnostics may be dominated by first-world powers, there are significant opportunities in substantial markets like Latin America. As Steve Jobs once said, "Innovation distinguishes between a leader and a follower." These emerging leaders are not just innovating; they are paving the way toward a healthier future in their communities. #DiagnosticInnovation #LatAmDx #MidThroughput #BiotechLatAm #ZentynelVC

Over the past 12 months or so, we have heard, seen and experienced the funding shortfalls across venture-backed companies not able to renew their #financing or complete their full funding rounds. We are now seeing this impacting larger #pharma budgets and strategic #investor activity who are being cautious with their funding. Some of this could be tied to hold-cash-until-the-US-election and/or better-to-be-overweighted-in-cash-over-summer #strategies. All this, of course, is in direct contrast to the incredible run the stock market is on driven largely by tech companies. Sector agnostic #investors are finding good returns in other industry segments. Committed #biotech investors, on the other hand, are being seduced with good clinical data and market success in other biopharma modalities compared to #cellandgene therapies (CGT) where autologous #celltherapies have faltered (temporarily in my opinion) to significantly increase market penetration, #genetherapies are being approved but struggling with reimbursement (particularly in Europe), the promise of CTs in large indications like auto-immune is far away and present an even large scale-up challenge, the translation of engineering other immune-cell types based on our CAR-T experience isn’t as easy as first (naively) thought, and the promise of allogeneic CGTs and/or CGT in solid tumors is so far not yet living up to perceived potential. In our opinion (Cell Therapy Group), this more restrictive financing environment for advanced therapies, is a retrenchment – a consolidation – a market-specific right-sizing of operations, investment, and strategy. What this is not, in our opinion, is a sign of any general biopharma shift away from a fundamental belief in the clinical and commercial potential of CGTs as one of the fastest growing pillars of health-care. That we are competing with the commercial potential of me-too obesity drugs and the hype around AI is a financial reality. That our clinical successes will and must be judged by the commercial viability of the products we bring to market is something to which we likely need to pay more attention. The smart people I’m surrounded by are already keenly aware of and building strategies around this to ensure tomorrow’s #CGTs are a better fit with the health economics we all face around the globe. We continue be very bullish on the potential of cell and gene therapies. What this is not is a belief that more of the same will drive different success. We are keenly aware that the CGTs of the 2030s – including the way we manufacture, deliver, and pay for them – will (and must) look very different than this generation of CGTs which have paved the way for the next evolution of commercially viable and clinical significant advanced therapies.

CSA Medical Inc Secures $53M Series D to Advance Breakthrough Chronic Bronchitis Therapy. CSA Medical, the developer of the innovative RejuvenAir® System, has closed an oversubscribed $53 million Series D financing round, co-led by TVM Capital Life Science and Yonjin Ventures. This funding will support CSA Medical's FDA premarket approval (PMA) process and the commercial launch of RejuvenAir in the U.S. The RejuvenAir System utilizes liquid nitrogen spray cryotherapy to treat chronic bronchitis—targeting the root cause of the disease. As chronic bronchitis affects over 9 million people in the U.S. alone, CSA Medical is poised to revolutionize care for this underserved population. With strong investor backing and an experienced team, the company is well-positioned for market impact, providing a groundbreaking solution to one of the largest subsets of COPD. #MedicalDevices #Cryotherapy #ChronicBronchitis #HealthcareInnovation #COPD